<DOC>
	<DOCNO>NCT02351739</DOCNO>
	<brief_summary>Study Combination ACP-196 Pembrolizumab Subjects With Platinum Resistant Metastatic Urothelial Cancer</brief_summary>
	<brief_title>Study Combination ACP-196 Pembrolizumab Subjects With Platinum Resistant Urothelial Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Men woman ≥ 18 year age Histologically cytologically confirm urothelial carcinoma bladder mixed histology bladder cancer Metastatic bladder cancer disease progression platinumbased chemotherapy Any primary site urothelial carcinoma include upper tract , renal pelvis , bladder , ureter Prior therapy ≥ 1 systemic chemotherapy regimens urothelial carcinoma Presence radiographically measurable disease ( define presence ≥ 1 lesion measure ≥ 10 mm [ ≥ 15 mm lymph node ] ECOG performance status 0 1 Prior malignancy ( bladder cancer ) , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer subject disease free ≥ 2 year limit survival &lt; 2 year . Known central nervous system metastases and/or carcinomatous meningitis Malabsorption syndrome , disease significantly affect gastrointestinal function Significant cardiovascular disease uncontrolled symptomatic arrhythmia , congestive heart failure , myocardial infarction within 6 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>